BGB-16673
BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other lymphomas.
≈ 1 min read
BGB-16673. encyclopegia.org, snapshot enwiki-001362666655. /a/bgb-16673
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BGB-16673 is an investigational new drug that is being evaluated by BeOne Medicines for the treatment of relapsed and refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and other lymphomas. BGB-16673 is a proteolysis targeting chimera (PROTAC) that acts by using the ubiquitin-proteasome system to target Bruton's tyrosine kinase (BTK) for degradation.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1362666655 under CC BY-SA 4.0; modifications have been made.